Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Semin Thromb Hemost ; 28(2): 215-26, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11992244

ABSTRACT

We used a canine and a murine model of von Willebrand disease (vWD) to study the in vivo effects of recombinant von Willebrand factor (vWF). Two preparations were used: (1) a fully processed mature vWF; this was achieved by coexpression of furin. (2) A preparation containing unprocessed pro-vWF, the propeptide still covalently linked to mature vWF. Both preparations induced an increase in canine and murine factor VIII:C (FVIII), which was sustained even when vWF antigen had been removed from the circulation. vWF multimers were analyzed in the plasma samples after infusion using ultra high-resolution 3% agarose gels to allow the separation of homoforms and heteroforms of the vWF polymers. Administration of pro-vWF to dogs with severe vWD resulted in the removal of the propeptide and maturation of vWF in the circulation, indicating that the propeptide cleavage from unprocessed vWF can occur extracellularly. This suggests that the vWF propeptide, besides being derived from the Weibel-Palade bodies of endothelial cells after stimulation, can also be cleaved by pro-vWF in plasma. Using a murine model of vWD, the involvement of the low-density lipoprotein receptor-related protein (LRP) in the clearance of FVIII was established. The low levels of FVIII observed in the absence of vWF are due to an enhanced clearance of FVIII by binding to LRP and removal from the circulation through endocytosis. Administration of the receptor-associated protein (RAP) as a recombinant fusion protein to vWF knockout mice significantly improved the in vivo recovery of recombinant FVIII and the survival time of otherwise rapidly cleared FVIII.


Subject(s)
Molecular Probe Techniques , von Willebrand Diseases/drug therapy , von Willebrand Factor/pharmacology , Animals , Dimerization , Disease Models, Animal , Dogs , Factor VIII/drug effects , Factor VIII/metabolism , Humans , Infusions, Parenteral , LDL-Receptor Related Protein-Associated Protein , Low Density Lipoprotein Receptor-Related Protein-1 , Mice , Mice, Knockout , Protein Precursors/administration & dosage , Protein Precursors/metabolism , Protein Precursors/pharmacokinetics , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Structure-Activity Relationship , von Willebrand Diseases/metabolism , von Willebrand Factor/administration & dosage
2.
Histochem Cell Biol ; 117(2): 123-9, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11935288

ABSTRACT

Von Willebrand factor (vWF) is synthesized in endothelial cells as pre-pro-vWF and processed intracellularly to propeptide (vWFpp) and mature vWF. Recombinant pro-vWF when infused into animals can also be processed extracellularly in vivo. Within 1 h of infusion in a dog and mice the multimer pattern changed to that typically seen in mature vWF indicating that propeptide cleavage from unprocessed vWF occurs extracellularly in the circulation. Incubation of a recombinant pro-vWF preparation with canine and human vWF-deficient plasma induced a time-dependent decrease in pro-vWF antigen and an increase in vWFpp antigen without changing total vWF antigen or collagen-binding activity. Multimer analysis showed the gradual transformation of the pro-vWF multimers to mature vWF multimers and cleaved vWFpp was visualized on autoradiograms of SDS-polyacrylamide electrophoresis gels using (125)I-labeled pro-vWF. When recombinant pro-vWF was incubated with increasing amounts of purified thrombin, the extent of pro-vWF processing was dose dependent. The specific cleavage of vWFpp was confirmed by immunoblots using an anti-vWFpp antibody and by amino-terminal amino acid analysis. Hirudin preconditioning of vWF-deficient mice attenuated processing of infused recombinant pro-vWF suggesting that thrombin plays a part in the processing events in vivo.


Subject(s)
Protein Processing, Post-Translational , von Willebrand Factor/metabolism , Animals , Humans , Protein Precursors/genetics , Protein Precursors/metabolism , Recombinant Proteins/metabolism , Thrombin/metabolism , von Willebrand Factor/genetics
3.
Thromb Haemost ; 88(6): 1003-11, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12529752

ABSTRACT

The development of inhibitory antibodies is a serious complication in hemophilic patients, severely compromising therapeutic success. Bleeding episodes in affected patients are controlled by treatment with a plasma-derived prothrombin complex concentrate (PCC), activated PCC (APCC) or recombinant activated factor VII. We hypothesized that a recombinant two-component agent consisting of recombinant prothrombin (rfII) and activated factor X (rfXa) would have substantial fVIII bypassing activity and could be a safe alternative therapeutic option. To test this hypothesis we assembled an agent in vitro solely consisting of rfII and rfXa at a molar ratio of 37,500:1. These factors are believed to be responsible for the activity of APCC preparations. Recombinant fX, used as the source for fXa generation, and rfII were purified from serum-free and protein-free conditioned media of stably transfected CHO and BHK tissue culture cells, respectively. Activation of rfX to rfXa was accomplished by the plant protease ficin, obviating the need for a protease derived from a human or animal source. We found that in vitro the complex reduced the abnormally prolonged activated partial thromboplastin time (APTT) of a high-titer fVIII inhibitor plasma similar to an APCC preparation. Furthermore, addition of increasing amounts of rfII/rfXa to inhibitor plasma resulted in a linear dose-dependent increase in the rate of thrombin generation. In a rabbit fVIII inhibitor model, treatment with rfII/rfXa statistically significantly reduced the intensity of the abnormal cuticle bleeding. In the Wessler test, rfII/rfXa showed no thrombogenicity. These data show that a well-defined, particularly safe and efficacious agent with fVIII bypassing activity can be generated from recombinant fII and fXa.


Subject(s)
Factor VIII/metabolism , Prothrombin/therapeutic use , Animals , Blood Coagulation/drug effects , CHO Cells , Cell Line , Cricetinae , Factor VIII/antagonists & inhibitors , Factor Xa/genetics , Factor Xa/isolation & purification , Factor Xa/therapeutic use , Ficain , Humans , In Vitro Techniques , Partial Thromboplastin Time , Prothrombin/genetics , Prothrombin/isolation & purification , Rabbits , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/therapeutic use , Safety , Thrombin/biosynthesis , Thrombosis/etiology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...